Dermatology specialist Galderma (SWX:GALD) announced on Friday that its regenerative biostimulator Sculptra has received EU Medical Device Regulation (MDR) certification, extending its use beyond facial applications to the gluteal area, posterior thighs, décolletage, and upper arms.
This expanded indication positions Sculptra to address broader aesthetic goals, including improvements in skin quality, firmness, lift, projection, and contour.
Clinical studies show progressive enhancements across these body areas, including improved skin texture and cellulite appearance.
Galderma said that the certification affirms Sculptra's safety, efficacy, and quality as a regenerative biostimulator. The company noted rising patient demand for comprehensive aesthetic solutions, with nine out of ten women reporting concerns beyond the face.
Growing interest in non-surgical body treatments, particularly for gluteal shaping, underscores the relevance of Sculptra's collagen and elastin–boosting effects.
Neola Medical secures US patent for disposable lung monitoring probes
Remington Medical's VascuChek 2.0 Cordless Bluetooth-Enabled Doppler Secures FDA Clearance
Aetna to launch generative AI-powered conversational experience
Maxx Orthopedics Receives FDA 510(k) Clearance for Its Libertas® Bipolar Hip System
Ascletis Pharma announces ASC36 and ASC35 co-formulation for clinical development
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies
Nurami Medical completes Phase 1 milestones in EIC-backed grant for Artifix
Organon to sell JADA System to Laborie for up to USD465m
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
BD launches IVDR-certified self-collection solution to expand global access to HPV testing
Oticon launches Oticon Zeal, a discreet, fully featured in-the-ear hearing aid
Halozyme Therapeutics announces Q3 2025 release date
Samsung to invest USD110m in GRAIL and commercialise cancer detection test Galleri in Asia